{
  "meta": {
    "name": "DVO Osteoporose App — End-to-End Cases (Block 1, fixed)",
    "version": "1.0.0",
    "created_date": "2026-01-04",
    "rules_fixed": [
      "Age rows are age groups: 50 covers [50,55), etc.",
      "T-score between bins maps to next worse bin; clamped to row-available bins.",
      "DEGAM guidance is default; DVO mainstream shown as deviation/context where relevant."
    ],
    "dependencies": [
      "DVO_Threshold_Tables_Bundle_v1.0.0.json",
      "DVO_RF_Katalog_Rohdaten_v0.5.json",
      "DVO_lookup_pseudocode_v1.txt",
      "DVO_therapy_engine_pseudocode_v1.txt",
      "DVO_contraindication_pseudocode_v1.txt"
    ]
  },
  "cases": [
    {
      "case_id": "e2e_01",
      "title": "Case finding ohne Anlass (keine RF, keine Fraktur)",
      "inputs": {
        "sex": "female",
        "age_years": 62,
        "rf_selected": [],
        "events": {
          "fracture": []
        },
        "dxa": {
          "tscore_total_hip": null
        }
      },
      "computed": {
        "age_bin": 60,
        "lookup_mode": "WITHOUT_BMD"
      },
      "expected": {
        "workflow": {
          "case_finding": "basisdiagnostik_and_dxa_recommended"
        },
        "risk_band": "<3% (keine RF/BMD-basierte Schwellenüberschreitung)",
        "therapy_level1": "no_specific_drug",
        "therapy_level2": "none"
      }
    },
    {
      "case_id": "e2e_02",
      "title": "DXA vorhanden: Grenzfall (T-Score Zwischenwert → nächst schlechter), RF: Elternteil Hüftfraktur",
      "inputs": {
        "sex": "female",
        "age_years": 67,
        "rf_selected": [
          "rf_parent_hip_fracture"
        ],
        "rr_selected": [
          1.3
        ],
        "dxa": {
          "tscore_total_hip": -2.8
        }
      },
      "computed": {
        "age_bin": 65,
        "tscore_mapped": {
          "3%": "-2.0",
          "5%": "-2.5",
          "10%": "-3.0"
        },
        "multiplier": 1.3,
        "required_factor": {
          "3%": 1.2,
          "5%": 1.5,
          "10%": 2.3
        },
        "risk_band": "3–<5% (1.3 ≥ 1.2, aber < 1.5)"
      },
      "expected": {
        "therapy_level1": "no_specific_drug (3–5% ohne Trigger)",
        "therapy_level2": "none",
        "transparency": [
          "T-Score -2.8 wurde konservativ gemappt (je Schwelle: 3%→-2.0, 5%→-2.5, 10%→-3.0)",
          "DEGAM/DVO: 3–5% → Therapie nur bei Triggern (stark/irreversibel oder imminent)"
        ]
      }
    },
    {
      "case_id": "e2e_03",
      "title": "GC-Langzeittherapie: hoher Multiplikator (führt hier zu ≥10%)",
      "inputs": {
        "sex": "male",
        "age_years": 72,
        "rf_selected": [
          "rf_gc_pred_gt_7_5mg_gt_3m"
        ],
        "rr_selected": [
          4.0
        ],
        "dxa": {
          "tscore_total_hip": -2.2
        }
      },
      "computed": {
        "age_bin": 70,
        "tscore_mapped": {
          "3%": "-1.5",
          "5%": "-2.0",
          "10%": "-2.5"
        },
        "multiplier": 4.0,
        "required_factor": {
          "3%": 1.1,
          "5%": 1.3,
          "10%": 1.7
        },
        "risk_band": ">=10% (4.0 ≥ 1.7)"
      },
      "expected": {
        "therapy_level1": "osteoanabolic (>=10%)",
        "therapy_level2": {
          "default_guidance": "DEGAM",
          "class": "osteoanabolic",
          "options": [
            "romosozumab",
            "teriparatide"
          ],
          "deviation_note": "DVO stärker (A: 'soll'), DEGAM Standard abgeschwächt (B: 'sollte')"
        }
      }
    },
    {
      "case_id": "e2e_04",
      "title": ">=10% ohne Fraktur: RA + TBS (Top-2-RF) → osteoanabol, DEGAM Standard",
      "inputs": {
        "sex": "female",
        "age_years": 75,
        "rf_selected": [
          "rf_rheumatoid_arthritis",
          "rf_tbs_zscore_minus_2_5"
        ],
        "rr_selected": [
          2.7,
          1.8
        ],
        "dxa": {
          "tscore_total_hip": -2.6
        }
      },
      "computed": {
        "age_bin": 75,
        "tscore_mapped": {
          "3%": "-1.0",
          "5%": "-2.0",
          "10%": "-3.0"
        },
        "multiplier": 4.86,
        "required_factor": {
          "3%": 1.2,
          "5%": 1.1,
          "10%": 1.2
        },
        "risk_band": ">=10% (4.86 ≥ 1.2)"
      },
      "expected": {
        "therapy_level1": "osteoanabolic (>=10%)",
        "therapy_level2": {
          "default_guidance": "DEGAM",
          "class": "osteoanabolic",
          "options": [
            "romosozumab",
            "teriparatide"
          ],
          "deviation_note": "DVO stärker (A: 'soll'), DEGAM Standard abgeschwächt (B: 'sollte')"
        },
        "transparency": [
          "RF-Top2-Regel: RA (2.7) und TBS -2.5 (1.8) gewählt; Multiplikation = 4.86"
        ]
      }
    }
  ]
}